Experimental eye pills can help blind mice see again.
Recently, there have been a number of recent developments in the field of international medical health that continue to attract the attention of the industry and the public. Sensory cell aging is a major cause of many causes of blindness, including age-related macular degeneration (AMD) and retinal pigmentation (RP). These diseases affect about 2 billion people worldwide and are the leading cause of vision loss and blindness.
In addition to the profound effects on independence and quality of life, vision loss is estimated to cause an annual global economic loss of about $4 trillion through medical expenditure and lost productivity. However, in the deeper intraocular retinal neural structure, the neural structure that maintains its integrity and function remains intact and is capable of functioning normally. The problem is that without sensory cells, these surviving cells no longer receive light signals, which are essential for transmitting visual information to the brain.
Therefore, the remaining retinal circuitry has become an important target for scientists trying to restore photosensitivity. Existing methods include gene therapy, which is only applicable to a small fraction of patients with specific mutations. There are also e-retinal prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina P Rostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina P Rostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses, eRetina Prostheses photosensitive medicines have produced encouraging safety effects, but these safety results are being taken in a normal light.
It is still difficult to restore high-quality visual function below normal levels. A collaboration led by the Catalonia Institute for Bioengineering (IBEC) has now developed a new class of photosensitive small molecule drugs designed to restore important visual function in blind vision in animal models. These findings were published in the Journal of the American Chemical Society.
These compounds are designed to do some of the work typically performed by photoreceptors. They can be injected into the eye, in combination with other ophthalmic drugs, or even used as an ophthalmic, both without the need for genetic modification or implantation equipment. These compounds do not cure blindness because they do not solve the causes of vision loss.
But they are very effective in restoring vision and they achieve this by a very simple, possibly patient-friendly method, explains Pau Gorostiza, head of the IBEC research group on nanosensors and nanosensors. It should be pointed out that the above content is based on international public research findings and is for reference in HealthCop and does not constitute clinical advice. If you have any health questions, please consult professional medical personnel.
